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It is now well-established that the brain, although immune privi-
leged, has fundamental interactions with elements of the immune
system. Perhaps, one of the most exciting aspects of such neuro-
immune communication, has been the notion that peripheral
derived immune factors (e.g., lymphocytes and cytokines), as well
as central glia (particularly microglia) are thought to participate
in the modulation of a variety of psychiatric and neurological
conditions. At the very least, microglial and cytokine responses
are though to shape some aspects of disease progression and pos-
sibly the emergence of comorbid features. One basic mechanism
through which immune cells (including microglia) and soluble
immunotransmitters could influence a variety of brain conditions
is via changes in neuroplasticity.
Virtually all psychiatric (e.g., major depression) and neuro-
logical [e.g., Parkinson’s (PD) and Alzheimer’s disease (AD)]
disorders have been associated with changes in neuroplasticity
and neuroinflammatory processes (Frank-Cannon et al., 2009;
Hayley, 2011). Indeed, reductions of adult hippocampal neuro-
genesis, diminished cortical dendritic arbors, deficits in long-
term potentiation (LTP) and impaired synaptogenesis have all
been reported (Perederiy and Westbrook, 2013; Na et al., 2014).
Papers in the present special topic discuss evidence that the
pro-inflammatory factors [e.g., interleukin-1β (IL-1β), tumor
necrosis factor-α (TNF-α)] provoke neuroplastic deficits, whereas
anti-inflammatory and neurotrophic cytokines enhance neuro-
plasticity and might even have neuroprotective or regenerative
effects (e.g., Hayley and Litteljohn, 2013).
This Frontiers Research Topic is comprised of a series of arti-
cles that deal with how brain-immune system interactions occur
and their influence on neuroplasticity. Several interrelated key
issues were touched upon, namely: (1) The specific neuroinflam-
matory pathways that contribute to neurodegeneration and how
targeting these pathways might facilitate recovery by promoting
neuroplasticity, (2) The role of pro-inflammatory cytokines and
immune cells in the cognitive and behavioral deficits associated
with head injury or neurological illness, (3) How inflammatory
environmental stressors promote deficits in neuroplasticity and
behavioral functioning, and (4) How signaling molecules of the
immune system, particularly trophic cytokines, might be utilized
as novel antidepressant or neurorecovery agents.
While the housekeeping functions of central and periph-
eral inflammatory immune cells are normally beneficial and
buffer neurons against deleterious insults, the over-activation of
neuroinflammatory cascades is exceedingly dangerous to neu-
rons. For instance, in the case of PD, as pointed out in the
article by Pitossi’s group in this special issue, accumulating data
support a link between PD and enhanced microglial and pro-
inflammatory cytokine (e.g., TNF-α and IL-1β) responses (Leal
et al., 2013). Similarly, Rivest and colleagues provide compelling
evidence to suggest that key components of the IL-1 signaling
system, namely IL-1RAcPb, influence the long-term survival of
neurons exposed to an excitotoxic insult (Gosselin et al., 2013).
Understanding exactly why pro-inflammatory factors become
dysregulated in the first place has been an enormous challenge
and likely reflects a combination of events, including genetic
mutations in “plasticity” and “inflammatory” genes [e.g., Brain-
derived neurotrophic factor (BDNF) Val66Met polymorphism
and Leucine Rich Repeat Kinase (LRRK2), respectively], coupled
with exposure to environmental insults.
Developing means of enhancing the endogenous repair mech-
anisms represents one viable approach to battling mental health
and neurological conditions. In this regard, taking advantage
of the natural capacity of immune factors to exhibit “learned”
responses and to traffic to and interact with cells at sites of
pathologymay be of particular importance. Hayley and Litteljohn
(2013), in this issue, discuss the cytokine, erythropoietin (EPO),
with respect to its potential antidepressant effects. Indeed, EPO
is considered as one of a potential next wave of agents with
antidepressant properties posited to stem from their ability to
modulate aberrant neuroplasticity in emotion regulatory brain
circuits. Conversely, cytokines with primarily pro-inflammatory
properties, such as TNF-α and IL-1β, as outlined in the Audet
and Anisman (2013) paper, have been reported to adversely
affect neuroplasticity and promote depressive illness. Mallimo
and Kusnecov (2013) go further still to illustrate how neuroin-
flammatory cytokines affect behavioral outcomes through their
impact on neuropeptide signaling pathways. Ultimately, this line
of investigation could identify novel targets for treating stressor
related disorders.
Besides symptom management, it is of particular impor-
tance to develop strategies that address the underlying pathology
and either reverse/stabilize neuronal derangements or alter-
natively, promote compensatory recovery of existing circuits.
In this regard, Munemasa and Kitaoka (2013), in this issue,
report intriguing findings indicating a role for TNF-α in reti-
nal cell degeneration in glaucoma and raise the possibility that
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modulation of BDNF might not only have neuroprotective func-
tions, but also facilitate axonal regeneration. Interestingly, the
article by Holahan’s group also highlights the role of pro-
inflammatory factors in cerebral concussion and head injury
(Patterson and Holahan, 2012). This is a case where it is critical
to assess the time-dependent emergence of neurological seque-
lae that might coincide with the progression of inflammatory
cascades. Thus, anti-inflammatory treatments might have pro-
phylactic utility in such cases and identification of inflammatory
biomarkers of disease progression might help in “fine tuning” the
treatment strategy adopted for individual cases.
The intersection between genetic and pharmacological based
approaches for brain conditions is a particularly important area.
As reported by Liu et al. (2014) in this issue, the use of induced
pluripotent stem cell (iPSC) technology allows one to tailor
specific cell replacement approaches using an individual’s own
somatic cells. In addition to potentially replacing loss neurons in
cases of neurodegeneration, the iPSC approach might be useful
in the remediation of aberrant structural changes through the
enhanced long-term expression of BDNF or other trophic fac-
tors. Indeed, central infusion of iPSC-derived neural cells that
co-expressed BDNF increased subventricular zone neurogenesis
and blunted the corticoid response to a stressor (Liu et al., 2014).
Finally, Rivest and colleagues have been at the forefront of
examining neuroimmune interactions and brain plasticity and
in this issue they provide captivating evidence to suggest that
defects in monocyte subsets contribute to cognitive dysfunc-
tion in AD. Importantly, they show that administration of the
trophic cytokine, macrophage-colony stimulating factor, reversed
the cognitive decline and hematopoietic deficits observed in a
transgenic model of AD (Naert and Rivest, 2012).
Ultimately, it is important to consider both the protective
and destructive aspects of the inflammatory immune system and
how the microenvironment in which these molecules act is crit-
ical. Indeed, beneficial vs. deleterious effects can even vary over
time with any particular illness. As pointed out by Patterson and
Holahan, this might explain the lack of positive clinical effects
for general use of broad-spectrum anti-inflammatory drugs (e.g.,
NSAIDs) in the treatment of brain pathologies. In effect, the path
forward should involve drugs aimed at targeting specific inflam-
matory factors (e.g., TNF-α, IL-1β, IFN-γ) identified by several
laboratories, including those of Anisman et al., depending upon
the particular condition and stage of disease. That said, boosting
protective aspects of immunity, as reported by papers by each of
Rivest et al., as well as Hayley, suggest that interventions that ele-
vate endogenous trophic cytokines could have immense clinical
benefits.
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